OncTimes Talk Podcast Series
Discussions on CLL
CLL Frontline Treatment - With Sameer A. Parikh, MBBS and Alessandra Ferrajoli, MD
Dr. Parikh and Dr. Ferrajoli summarize and discuss the findings of the CLL Frontline Treatment study (Eichhorst, NEJM).
Background: Randomized trials of Venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS and Alessandra Ferrajoli, MD
Dr. Parikh and Dr. Ferrajoli summarize and discuss the findings of the Relapsed CLL study (Brown, NEJM).
Background: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superior to ibrutinib with respect to overall response (the primary end point).
Pirtobrutinib after Covalent BTK Inhibitor - Double Refractory CLL - With Sameer A. Parikh, MBBS and Alessandra Ferrajoli, MD
Dr. Parikh and Dr. Ferrajoli summarize and discuss the findings of the Double Refractory CLL study (Mayo, NEJM).
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to reestablish BTK inhibition.